Advertisement

New Ragweed Allergy Immunotherapy Gets Votes of Confidence from FDA Advisers — Physician’s First Watch

Medical News |
January 29, 2014

New Ragweed Allergy Immunotherapy Gets Votes of Confidence from FDA Advisers

By the Editors

An FDA advisory committee voted on Tuesday in support of the safety and efficacy of an experimental sublingual tablet to treat ragweed allergy. Adults with ragweed allergy would take Ragwitek — made up of ragweed pollen extracts — daily beginning at least 12 weeks before the start of ragweed pollen season until the season ends.

The FDA typically follows the advice of its advisory panels when making drug approval decisions, but is not required to do so.

Reader Comments (1)

J ROSS HESTER Other Healthcare Professional, Internal Medicine, Edcom Associates Holistic Health

Having myself successfully used homeopathic products with identical modes of administration and made from what homeopaths call "essences" of various pollens using the homeopathic principle of "like cures like," I can't stifle a chuckle at the FDA "vote of confidence for allergy immunotherapy." The more things change -the more they remain the same.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement